ArticleEuropean journal of nuclear medicine and molecular imaging2026
[18 F]FDG PET unveils a cachexia-specific multiorgan metabolic phenotype and identifies patients with poor prognosis in locally advanced rectal cancer.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer cachexia is a debilitating syndrome that profoundly impacts survival, yet its systemic metabolic characteristics and prognostic drivers in locally advanced rectal cancer (LARC) remain poorly defined. This study aimed to comprehensively profile the host’s metabolic response in LARC-associated cachexia using [18 F]FDG PET-CT and to evaluate its prognostic implications.
methodsIn this retrospective analysis, 131 LARC patients were stratified by cachexia status. Receiver operating characteristic (ROC) analysis was used to identify the most discriminative metabolic parameters. Structural equation modeling was applied to assess the mediating role of systemic metabolism between primary tumor metabolic tumor volume (MTV) and cachexia. Survival analysis was conducted using Kaplan–Meier curves and Cox proportional hazards models, with overall survival (OS) as the primary endpoint.
resultsCachectic patients displayed a distinct systemic metabolic profile. First, a coordinated reduction in aortic, hepatic, and pancreatic FDG uptake emerged as a hallmark of systemic metabolic suppression. Conversely, adipose tissue exhibited a paradoxical hypermetabolism that was not only preserved but markedly accentuated across all depots after normalization to aortic uptake, revealing a consistent and systemic shift in metabolic partitioning. Path analysis within our model revealed significant direct paths from hypometabolism in the aorta and pancreas to cachexia. The effect of primary tumor MTV was channeled through both direct and indirect routes, with subcutaneous fat metabolism exhibiting the most substantial mediating effect. Critically, survival analysis pinpointed subcutaneous fat glucose uptake (SubFat SUVmax) from this metabolic network, validating it in multivariate analysis as a powerful independent prognostic factor that surpassed the clinical diagnosis of cachexia.
conclusionThis study delineates a comprehensive metabolic landscape of cachexia in LARC, revealing a systemic energy imbalance in which adipose tissue hypermetabolism acts as both a key pathophysiological mediator and a superior prognostic biomarker compared to clinical cachexia diagnosis. These findings support a shift from phenotypic to metabolic stratification in the management of cancer cachexia.
Indexed as
Identifiers
41410873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.